This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Yu Qian - Innovator in Natural Killer Cell Production
Introduction
Yu Qian is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of cellular biology. He has developed innovative methods that enhance the production of natural killer cells, which are crucial for immune responses. His work is particularly relevant in the context of therapeutic applications for various diseases.
Latest Patents
Yu Qian holds a patent for a method titled "Method for producing natural killer cells from pluripotent stem cells." This patent outlines a process for efficiently generating natural killer cells from induced pluripotent stem cells. The method involves culturing pluripotent stem cells in a specialized culture medium to produce CD56+/CD3− immune cells, which are essential for effective immune function. He has 1 patent to his name.
Career Highlights
Yu Qian is currently affiliated with Takeda Pharmaceutical Company Limited, where he continues to advance research in immunology and cell therapy. His work at Takeda emphasizes the importance of innovative approaches to enhance immune cell production, which can lead to breakthroughs in cancer treatment and other immune-related conditions.
Collaborations
Yu has collaborated with notable colleagues, including Hui-Hsin Chang and Xi Shi, who share his commitment to advancing research in the field of immunology. Their combined expertise fosters a collaborative environment that drives innovation and discovery.
Conclusion
In summary, Yu Qian is a key figure in the development of methods for producing natural killer cells, with a focus on enhancing therapeutic applications. His contributions to the field are paving the way for future advancements in immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
